Skanda Life Sciences

Executive Summary

Skanda Life Sciences is a Bangalore-based contract research organization (CRO) that provides end-to-end drug discovery and preclinical services, with a focus on oncology and infectious disease. Founded in 2012, the company employs between 200-500 people and offers integrated capabilities including natural product extraction, medicinal chemistry, biology, DMPK, and toxicology. Skanda serves pharmaceutical, biotech, and nutraceutical clients, leveraging its platform to accelerate early-stage drug development. As a private company with no disclosed funding or valuation, Skanda operates as a service provider rather than a drug developer, generating revenue through client contracts. Its position in India’s growing CRO market and its specialized focus on high-demand therapeutic areas position it as a potential partner for global pharma and biotech firms seeking cost-effective R&D outsourcing. Skanda Life Sciences has a stable business model underpinned by recurring service revenue, but its lack of proprietary pipeline limits upside compared to drug developers. The company's growth trajectory depends on expanding client relationships and service capabilities. With no disclosed financials or near-term milestones, the conviction score is moderate. Key catalysts include securing a strategic partnership with a major pharmaceutical company, expanding its service portfolio into new modalities like biologics or ADME, and investing in new laboratory infrastructure to increase capacity. These events could enhance Skanda’s competitive position and revenue growth.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-20 pharma company for oncology or infectious disease programs50% success
• Q2 2027Expansion of preclinical service capabilities into biologics or gene therapy40% success
• Q1 2027Investment in new laboratory facilities to double capacity in Bangalore60% success